• http://www.revobiologics.com/sites/default/files/_rotation-images/slide-3-new.jpg

    Making a Real Difference

    With an unwavering commitment to patients with rare diseases, rEVO Biologics is moving healthcare forward.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/rotation_3.jpg

    Solutions for Rare Diseases

    rEVO Biologics is a rare disease company delivering on the promise of innovative therapies.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/slide-2-new.jpg

    Delivering Innovative Therapies

    Through groundbreaking technology, rEVO Biologics is changing the way rare diseases are treated.

News Releases

Study Reports Significant Increase in Incidence of Preeclampsia, a...

FRAMINGHAM, Mass., Oct. 22, 2015 — A study published recently in the American Journal of Perinatology reports a dramatic increase in the incidence of preeclampsia in the United States.  Preeclampsia and early onset preeclampsia have grown 67 percent and 140 percent respectively over the past two decades. The rise in this life-threatening condition outpaces that of some of the United States’ most challenging public health concerns, including diabetes, obesity and Alzheimer’s disease.  Preeclampsia is one of the top six causes of maternal mortality in the United States and is associated with infant death and potentially lifelong complications for the mother and newborn.

Preeclampsia is a complication of pregnancy that typically develops after 20 weeks gestation.  Early onset preeclampsia is a severe form that occurs before 34 weeks gestation.  The condition is characterized by high blood pressure and is thought to be the result of an...

Contact Us +